Acting On Glycosyl Compound (3.2) (e.g., Glycosidases Lysozyme, Nucleosidases, Cellulase, Etc.) Patents (Class 424/94.61)
-
Patent number: 8124073Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 8, 2008Date of Patent: February 28, 2012Assignee: Genzyme CorporationInventor: James Stefano
-
Publication number: 20120045425Abstract: The invention relates to ?4,5 glycuronidase, related compositions, and methods of use thereof.Type: ApplicationFiled: April 8, 2011Publication date: February 23, 2012Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: JAMES R. MYETTE, ZACHARY SHRIVER, GANESH VENKATARAMAN, RAM SASISEKHARAN, MAITLAND W. MCLEAN
-
Publication number: 20120039985Abstract: Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-?1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia.Type: ApplicationFiled: November 6, 2009Publication date: February 16, 2012Inventors: Ebo D. de Muinck, Jose R. Conejo-Garcia
-
Patent number: 8114437Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.Type: GrantFiled: February 3, 2006Date of Patent: February 14, 2012Assignee: Intarcia Therapeutics, Inc.Inventors: Catherine M. Rohloff, Guohua Chen, Andrew S. Luk, Rupal A. Ayer, Paul R. Houston, Michael A. Desjardin, Pauline Zamora, Stan Lam
-
Publication number: 20120034187Abstract: Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: October 21, 2011Publication date: February 9, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Punit BHARDWAJ, Josee BORDELEAU, Pasquale FORGIONE, Elise GHIRO, Vida GORYS, Nathalie GOUDREAU, Sylvie GOULET, Teddy HALMOS, Jean RANCOURT
-
Publication number: 20120036599Abstract: This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams.Type: ApplicationFiled: April 5, 2011Publication date: February 9, 2012Applicant: DYADIC INTERNATIONAL , INC.Inventors: Alexander Vasilievich Gusakov, Peter J. Punt, Jan Cornelis Verdoes, Arkady Panteleimonovich Sinitsyn, Elena Vlasenko, Sandra Wilhelmina Agnes Hinz, Mark Gosink, Zhijie Jiang, Jacoba Van der Meij
-
Publication number: 20120030838Abstract: This invention relates to novel enzymes and novel methods for producing the same. More specifically this invention relates to a variety of fungal enzymes. Nucleic acid molecules encoding such enzymes, compositions, recombinant and genetically modified host cells, and methods of use are described. The invention also relates to a method to convert lignocellulosic biomass to fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass. The invention also relates to methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, deinking and biobleaching of paper and pulp, and treatment of waste streams.Type: ApplicationFiled: April 5, 2011Publication date: February 2, 2012Applicant: DYADIC INTERNATIONAL, INC.Inventors: Alexander Vasilievich Gusakov, Peter J. Punt, Jan Cornelis Verdoes, Arkady Panteleimonovich Sinitsyn, Elena Vlasenko, Sandra Wilhelmina Agnes Hinz, Mark Gosink, Zhijie Jiang, Jacobs Van der Meij
-
Publication number: 20120027848Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.Type: ApplicationFiled: July 28, 2011Publication date: February 2, 2012Applicant: Curemark LLCInventors: Joan M. Fallon, Matthew Heil
-
Publication number: 20120027674Abstract: Compositions and methods for use in preventing, inhibiting or reducing tumor cell growth comprising an effective amount of an active agent that kills IL-18 Receptor expressing T cells in admixture with a suitable diluent or carrier are described herein.Type: ApplicationFiled: July 21, 2011Publication date: February 2, 2012Applicant: BAYLOR RESEARCH INSTITUTEInventors: Hideki Ueno, Jacques F. Banchereau, Anna Karolina Palucka
-
Publication number: 20120023616Abstract: This invention provides a method for preventing or inhibiting infection with a plant-infecting microorganism and imparting resistivity to plants, a method for preparing plants having resistance to diseases caused by microorganisms such as plant pathogenic filamentous fungi, and a microbial pesticide formulation. The method for preventing or inhibiting infection of a host plant with plant-infecting microorganisms comprises degrading ?-1,3-glucan on cell walls of the microorganisms by ?-1,3-glucanase.Type: ApplicationFiled: March 16, 2010Publication date: January 26, 2012Applicant: NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCESInventors: Marie Nishimura, Yoko Nishizawa, Takashi Fujikawa, Ichiro Mitsuhara, Eiichi Minami, Keietsu Abe, Takashi Tachiki, Shigekazu Yano
-
Patent number: 8101393Abstract: The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a ?-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass.Type: GrantFiled: December 8, 2006Date of Patent: January 24, 2012Assignee: BP Corporation North America Inc.Inventors: Kevin A. Gray, Lishan Zhao, Michelle H. Cayouette
-
Patent number: 8097241Abstract: The invention is directed to a formulation and method for treating solid waste from animals. The formulation comprises a surfactant having antimicrobial activity, preferably a cationic surfactant, and a solvent, preferably water. The preferred cationic surfactant is a quaternary ammonium compound. The formulation may further include one or more of acids, bases, enzymes, oxidizing agents, foamants, colorants, and/or fragrances. The formulation is prepared as a concentrate composition for use with a suitable diluent, such as water. The diluted composition is applied to the waste as a pressurized jet of fluid, such as using a sprayer attached to a garden hose. The result is that the solid waste is substantially sanitized, disintegrated and/or deodorized.Type: GrantFiled: April 3, 2008Date of Patent: January 17, 2012Inventors: Lawrence Orubor, Ken Battle, Roman Bielski
-
Publication number: 20120003203Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of pathogen cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of infectious diseases.Type: ApplicationFiled: September 10, 2009Publication date: January 5, 2012Inventors: Yaffa Mizrachi-Nebenzahl, Ron Dagan
-
Publication number: 20120003202Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.Type: ApplicationFiled: June 25, 2011Publication date: January 5, 2012Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Pericles Calias, Jing Pan, Jan Powell, Lawrence Charnas, Thomas McCauley, Teresa Leah Wright, Richard Pfeifer, Zahra Shahrokh
-
Patent number: 8088612Abstract: A Dictyoglomus turgidum thermostable cellulase enzyme with both endocellulase activity and exocellulase activity that is able to degrade cellulose in the absence of scaffoldins and other cellulosomic proteins is provided. The use of the enzyme to degrade cellulosic materials to soluble sugars is also provided. Also described are nucleic acid constructs that encode and express the cellulase, and hosts transformed to contain the nucleic acid constructs.Type: GrantFiled: October 23, 2009Date of Patent: January 3, 2012Assignee: C5-6 Technologies, Inc.Inventor: Phillip J. Brumm
-
Publication number: 20110318327Abstract: Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.Type: ApplicationFiled: June 25, 2011Publication date: December 29, 2011Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Michael F. Concino, Pericles Calias, Jing Pan, Kevin Holmes, Paolo Martini, Alla Romashko, Muthuraman Meiyappan, Bohong Zhang, Andrea Iskenderian, Dianna Lundberg, Angela Norton, Bettina Strack-Logue, Yan Huang, Mary Alessandrini, Richard Pfeifer
-
Publication number: 20110318328Abstract: The Staphylococcus aureus bacteriophage phi11 endolysin has two peptidoglycan hydrolase domains (endopeptidase and amidase) and a SH3b cell wall-binding domain. In turbidity reduction assays, the purified protein can lyse untreated staphylococcal mastitis-causing pathogens, S. aureus and coagulase negative staphylococci (S. chronogenes, S. epidermis, S. hyicus, S. simulans, S. warneri, and S. xylocus), making it a strong antimicrobial protein and an effective candidate for treating multidrug-resistant staphylococci. Lytic activity is maintained at the pH (6.7) and the ‘free’ calcium concentration (3 mM) of milk. Truncated endolysin-derived proteins, containing just the endopeptidase domain, also lyse staphylococci, in the absence of the SH3b-binding domain.Type: ApplicationFiled: July 27, 2011Publication date: December 29, 2011Inventor: David M. Donovan
-
Patent number: 8084025Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.Type: GrantFiled: April 20, 2009Date of Patent: December 27, 2011Assignee: Curemark LLCInventor: Joan M. Fallon
-
Publication number: 20110311499Abstract: The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts.Type: ApplicationFiled: July 12, 2011Publication date: December 22, 2011Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATIONInventors: JOSEPH MOUGOUS, ALISTAIR BRIAN RUSSELL, MICHELE LEROUX
-
Publication number: 20110305737Abstract: A comprehensive, single agent cosmetic cream or lotion containing a high number of ingredients that target anti-aging in a defined manner. The cream or lotion contains a high number and variety of active substances that demonstrate excellent safety and efficacy in all of the various defined categories of skin aging, including but not limited to wrinkles, abnormal pigment or brown spots due to aging of the skin and an unexpectedly high efficacy in the reduction of redness and acne and rosacea blemishes.Type: ApplicationFiled: June 7, 2011Publication date: December 15, 2011Applicant: NY Derm LLCInventor: Macrene Alexiades-Armenakas
-
Publication number: 20110300201Abstract: The invention provides methods, compositions, systems, and kits that include an enzyme/substrate co-delivery system. The liquid delivery system includes at least one enzyme encapsulated in a water-soluble polymeric matrix and a substrate for the enzyme in a carrier liquid in which the polymeric matrix is insoluble. When water is added, the polymeric matrix is solubilized and enzyme is released from the matrix, permitting catalytic action upon the substrate.Type: ApplicationFiled: November 3, 2009Publication date: December 8, 2011Applicant: DANISCO US INC.Inventors: Nathaniel T. Becker, Michael Stoner, Mee-Young Yoon
-
Patent number: 8071350Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used as amylases to catalyze the hydrolysis of starch into sugars.Type: GrantFiled: April 7, 2010Date of Patent: December 6, 2011Assignee: Verenium CorporationInventors: Kevin A. Gray, Nahla Aboushadi, James B. Garrett
-
Publication number: 20110286937Abstract: The present invention provides a glycolipid-containing liposome. In such a glycolipid-containing liposome, the glycolipid includes a plant ceramide portion and a sugar chain portion. The present invention also provides a method of producing a glycolipid-containing liposome. This method includes the following steps of: A) providing a glycolipid in which the glycolipid includes a plant ceramide portion and a sugar chain portion; and B) mixing the provided glycolipid with a liposome raw material and subjecting the mixture to conditions in which a liposome is formed.Type: ApplicationFiled: February 18, 2009Publication date: November 24, 2011Applicants: GIFU UNIVERSITY, KATAYAMA CHEMICAL INDUSTRIES CO., LTD.Inventors: Makoto Kiso, Hideharu Ishida, Taiji Yamashita, Koichi Igarashi, Masahiko Hirai
-
Publication number: 20110280856Abstract: The invention provides highly purified ?-Gal A, and various methods for purifying it; ?-Gal A preparations with altered charge and methods for making those preparations; ?-Gal A preparations that have an extended circulating half-life in a mammalian host, and methods for making same; and methods and dosages for administering an ?-Gal A preparation to a subject.Type: ApplicationFiled: November 11, 2010Publication date: November 17, 2011Inventors: Richard F Selden, Marianne Borowski, Carol M. Kinoshita, Douglas A. Treco
-
Publication number: 20110280854Abstract: Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.Type: ApplicationFiled: January 6, 2010Publication date: November 17, 2011Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
-
Publication number: 20110280864Abstract: The present invention also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle.Type: ApplicationFiled: November 10, 2009Publication date: November 17, 2011Applicant: Board of Regents, The University of Texas SystemInventors: Keith P. Johnston, Maria Andrea Mazuski, Joshua Engstrom, Miguel Angelo Rodrigues
-
Publication number: 20110280853Abstract: Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.Type: ApplicationFiled: January 6, 2010Publication date: November 17, 2011Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
-
Publication number: 20110268721Abstract: The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation.Type: ApplicationFiled: May 11, 2011Publication date: November 3, 2011Applicant: Amicus Therapeutics, Inc.Inventors: Hung V. Do, Ken Valenzano, David J. Lockhart
-
Publication number: 20110256115Abstract: The invention relates to [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives. These [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives of selected phenolics are new, have a solubility in water higher than that of their parent O-?-D-Glcp-(1?-phenolic derivatives and have useful applications in cosmetic, nutrition and pharmaceutical compositions, such as treating or preventing oxidative stress, a cancer, a cardiovascular disease, a bacterial infection, a viral infection, a fungal infection, a UV-induced erythema, an allergy, a metabolism disorder, diabetes, an obesity, a hormonal disorder, a bone disease, a pain, a brain disease, a mouth or teeth disease, an inflammatory or immune disorder.Type: ApplicationFiled: December 22, 2009Publication date: October 20, 2011Applicant: LibragenInventors: Daniel Auriol, Aurélien Ginolhac, Fabrice Lefevre, Renaud Nalin
-
Publication number: 20110250251Abstract: The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least one DNA repair enzyme.Type: ApplicationFiled: May 5, 2011Publication date: October 13, 2011Inventors: Daniel H. Maes, Thomas Mammone, Kerri Goldgraben
-
Publication number: 20110250181Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.Type: ApplicationFiled: April 6, 2011Publication date: October 13, 2011Applicant: Protalix Ltd.Inventors: Yoseph SHAALTIEL, Gideon Baum, Daniel Bartfeld, Sharon Hashmueli, Ayala Lewkowicz
-
Publication number: 20110243914Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) whrein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoidof sulfydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.Type: ApplicationFiled: June 13, 2011Publication date: October 6, 2011Inventors: Ludger JOHANNES, David Grierson, Sylvie Robine, Jean-Claude Florent, Philipe Maillard, Jacky Roger
-
Publication number: 20110236429Abstract: The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides.Type: ApplicationFiled: August 21, 2007Publication date: September 29, 2011Inventors: Robert E. W. Hancock, Kai Hilpert, Artem Cherkasov, Christopher Fjell
-
Publication number: 20110236366Abstract: Described herein are methods to express and purify recombinant type 1 ribosome inactivating proteins. Included are methods for using recombinant cucurmosin as a therapeutic to treat cancer and infectious diseases.Type: ApplicationFiled: February 27, 2009Publication date: September 29, 2011Inventor: Mingang Chen
-
Publication number: 20110223233Abstract: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.Type: ApplicationFiled: April 29, 2011Publication date: September 15, 2011Applicant: Delpor, Inc.Inventors: FRANCIS J. MARTIN, ANTHONY A. BOIARSKI
-
Publication number: 20110223225Abstract: The present invention relates in general to the field of oil powders. In particular, the present invention relates to an oil composition that is in powder form at room temperature. One embodiment of the present invention is a solid oil powder that has a very high oil content.Type: ApplicationFiled: November 16, 2009Publication date: September 15, 2011Applicant: NESTEC S.A.Inventors: Raffaele Mezzenga, Stephane Ulrich
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110223117Abstract: Isolated ?-glucanases from Hypocrea tawa, Trichoderma reesei, and Trichoderma konilangbra are described, as well as oral care compositions containing the same. The oral care composition may be employed to prevent or reduce dental plaque.Type: ApplicationFiled: April 9, 2009Publication date: September 15, 2011Inventors: Steven Kim, Suzanne Lantz, Michael Pepsin
-
Publication number: 20110223148Abstract: Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.Type: ApplicationFiled: September 16, 2009Publication date: September 15, 2011Applicant: GENOMIDEA INC.Inventors: Yasufumi Kaneda, Yoshifumi Kawaguchi, Toshimitsu Itai
-
Publication number: 20110217283Abstract: The invention relates to a method for the production of a medicament containing a polypeptide comprising at least one recombinant carbohydrate-binding polypeptide, or a functional fragment or derivative of said carbohydrate-binding polypeptide in a form stable for storage. The polypeptide mentioned comprises polypeptides or functional derivatives thereof, which are fused with cytotoxically effective peptides to give fusion proteins, or which are linked to another polypeptide having a cytotoxic activity. Moreover, the invention describes further formulating of the disclosed medicaments to medicaments with different pharmaceutical forms.Type: ApplicationFiled: May 6, 2011Publication date: September 8, 2011Inventors: Oliver Gloger, Bernd W. Müller, Klaus Witthohn
-
Publication number: 20110206684Abstract: Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins.Type: ApplicationFiled: February 23, 2011Publication date: August 25, 2011Applicant: Prolacta Bioscience Inc.Inventor: Elena Maria MEDO
-
Publication number: 20110200575Abstract: Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms.Type: ApplicationFiled: April 28, 2011Publication date: August 18, 2011Applicant: Naidu LPInventors: A. Satyanarayan Naidu, A.G. Tezus Naidu, A.G. Sreus Naidu
-
Publication number: 20110200678Abstract: The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals.Type: ApplicationFiled: March 3, 2010Publication date: August 18, 2011Applicant: THE INDUSTRY METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTIOInventors: Sung Joo Hwang, Min Soo Kim, Jeong Soo Kim, Kwang Ho Cha, Won Kyung Cho, Jun Sung Park, Suk Jun Seo
-
Publication number: 20110196319Abstract: The present disclosure is directed to a cleansing solution and system for administering the cleansing solution to decontaminate a wound surface. A method and kit for decontaminating a wound surface is also provided.Type: ApplicationFiled: April 18, 2011Publication date: August 11, 2011Inventors: Edward F. Arscott, II, Irina Ganopolsky, George L. Grobe, III, Mark A. Heldreth, Joseph J. LiBrizzi, Hugo A. Pedrozo
-
Publication number: 20110182875Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.Type: ApplicationFiled: August 23, 2010Publication date: July 28, 2011Applicant: NexBio, Inc.Inventors: Fang Fang, Michael Malakhov
-
Publication number: 20110182986Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.Type: ApplicationFiled: April 5, 2011Publication date: July 28, 2011Applicant: TEMREL, INC.Inventors: Christopher J. Speirs, Peter Moir, Richard H. C. Williams, Michael S. Clark
-
Publication number: 20110182818Abstract: A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.Type: ApplicationFiled: July 1, 2009Publication date: July 28, 2011Inventor: Joan M. Fallon
-
Publication number: 20110178488Abstract: The invention is a sexual hygienic preparation comprising extract prepared from the milk of at least one equid animal. The preparation may contain medically/therapeutically acceptable additive(s) in specified cases. The preparation is formulated preferably as a feminine cleansing gel, feminine cleansing shampoo, feminine cleansing soap, vaginal suppository, vaginal pill, vaginal cleansing liquid, concentrate, water-soluble solid vaginal cleansing preparation, effervescent tablet, granulate, powder, lyophylized Lactobacillus preparation, spermicide preparation; adsorbent material such as dry or wet wipe, sanitary pad, vaginal suppository, containing sexual hygienic preparation.Type: ApplicationFiled: March 29, 2011Publication date: July 21, 2011Applicant: DOLHAY KLINIKA EGESZSEGUGYI KFT.Inventor: Dolhay BaLázs
-
Publication number: 20110171198Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicants: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH, ALTIF LABORATORIESInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20110158935Abstract: Disclosed are drug delivery systems for the delivery of small molecule and macromolecular drugs. More particularly, disclosed are substituted analogs of 3,6-di(alkyl-4 aminobutyl)-2,5-diketopiperazine (which may also be referred to DKP), their use in the formulation of both small molecule and macromolecular drugs including therapeutic, prophylactic and diagnostic agents, stabilizing agents and systems for their delivery.Type: ApplicationFiled: December 29, 2009Publication date: June 30, 2011Inventor: Kelly Sullivan Kraft